Accuray Incorporated Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended December 31, 2016; Reaffirms Earnings Guidance for the Fiscal Year 2017
January 01, 2017 at 02:31 am IST
Share
Accuray Incorporated announced unaudited consolidated earnings results for second quarter and six months ended December 31, 2016. For the quarter, the company's total net revenue was USD 87,502,000 against USD 108,912,000 a year ago. Loss from operations was USD 4,823,000 against USD 124,000 a year ago. Loss before provision for income taxes was USD 8,943,000 against USD 5,194,000 a year ago. Net loss was USD 9,369,000 or USD 0.08 per basic and diluted share against USD 6,027,000 or USD 0.08 per basic and diluted share a year ago. Adjusted EBITDA was USD 1,768,000 against USD 6,811,000 a year ago.
For the six months, the company's total net revenue was USD 174,008,000 against USD 198,543,000 a year ago. Loss from operations was USD 11,370,000 against USD 7,355,000 a year ago. Loss before provision for income taxes was USD 19,495,000 against USD 17,516,000 a year ago. Net loss was USD 19,295,000 or USD 0.24 per basic and diluted share against USD 19,053,000 or USD 0.24 per basic and diluted share a year ago. Adjusted EBITDA was USD 2,936,000 against USD 5,718,000 a year ago.
The company reaffirmed previously provided financial guidance for the fiscal year 2017. For the year, the company expects total revenue to be between USD 410 million to USD 420 million, representing growth of approximately 3% to 5% year-over-year. Adjusted EBITDA is expected to be between USD 32.0 million to USD 38.0 million representing growth of approximately 30% to 55% year-over-year. Gross Orders growth of approximately 5%.
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells, and supports solutions that are designed to deliver radiation treatments. Its solutions are designed to advance patient care during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, the Company also provides services, which include post-contract customer support (warranty period services and post warranty services), installation services, training, and other professional services.
Accuray Incorporated Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended December 31, 2016; Reaffirms Earnings Guidance for the Fiscal Year 2017
ACCURAY INCORPORATED 
